分组1 - Keros Therapeutics reported quarterly earnings of $3.62 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.01 per share, and showing an improvement from a loss of $1.21 per share a year ago, resulting in an earnings surprise of 36,300% [1] - The company posted revenues of $211.25 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 149.64%, compared to revenues of $0.08 million in the same quarter last year [2] - Keros Therapeutics shares have declined approximately 8.1% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$1.02 on revenues of $8.28 million, and for the current fiscal year, it is -$3.46 on revenues of $100.68 million [7] - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - CuriosityStream Inc. reported quarterly earnings of $0.01 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share, marking a significant improvement from a loss of $0.09 per share a year ago, indicating a 200% earnings surprise [1] Financial Performance - The company achieved revenues of $15.09 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.36%, compared to $12 million in revenues from the same quarter last year [2] - Over the last four quarters, CuriosityStream has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - CuriosityStream shares have increased approximately 115% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates for the upcoming quarter at -$0.02 on revenues of $14.2 million, and -$0.05 on revenues of $61.9 million for the current fiscal year [4][7] - The estimate revisions trend for CuriosityStream is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Film and Television Production and Distribution industry, to which CuriosityStream belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

While Clover Health Investments has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Clover Health Investments, Corp. (CLOV) came out with quarterly ear ...

Core Insights - ProAssurance reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share, but showing an improvement from $0.08 per share a year ago, resulting in an earnings surprise of -31.58% [1] - The company posted revenues of $269.76 million for the quarter, which was 0.33% below the Zacks Consensus Estimate and down from $282 million year-over-year [2] - ProAssurance shares have increased by approximately 44.4% since the beginning of the year, contrasting with a -3.9% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.20, with expected revenues of $270.08 million, and for the current fiscal year, the EPS estimate is $0.92 on revenues of $1.08 billion [7] - The estimate revisions trend for ProAssurance is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Insurance - Property and Casualty industry is ranked in the top 17% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Jack Henry reported quarterly earnings of $1.52 per share, exceeding the Zacks Consensus Estimate of $1.29 per share, and up from $1.19 per share a year ago, representing an earnings surprise of 17.83% [1] - The company posted revenues of $585.09 million for the quarter ended March 2025, which missed the Zacks Consensus Estimate by 0.30%, compared to $538.56 million in the same quarter last year [2] - Over the last four quarters, Jack Henry has surpassed consensus EPS estimates four times but has topped consensus revenue estimates only once [2] Market Context - Jack Henry shares have declined approximately 1.7% since the beginning of the year, while the S&P 500 has seen a decline of 3.9% [3] - The company's current Zacks Rank is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.46 on revenues of $612.98 million, and for the current fiscal year, it is $5.70 on revenues of $2.38 billion [7] - The outlook for the Computers - IT Services industry, to which Jack Henry belongs, is currently in the bottom 45% of over 250 Zacks industries, which may impact stock performance [8]

Core Viewpoint - Cirrus Logic reported strong quarterly earnings, significantly exceeding expectations, indicating robust performance in the semiconductor industry [1][2]. Financial Performance - The company achieved earnings of $1.67 per share, surpassing the Zacks Consensus Estimate of $1.15 per share, and up from $1.24 per share a year ago, representing a 45.22% earnings surprise [1] - Revenues for the quarter reached $424.46 million, exceeding the Zacks Consensus Estimate by 11.70%, and up from $371.83 million year-over-year [2] - Over the last four quarters, Cirrus Logic has consistently surpassed consensus EPS and revenue estimates [2] Market Performance - Cirrus Logic shares have declined approximately 1.1% year-to-date, while the S&P 500 has decreased by 3.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - Current consensus EPS estimate for the upcoming quarter is $0.83 on revenues of $341.24 million, and for the current fiscal year, it is $6.82 on revenues of $1.87 billion [7] - The outlook for the semiconductor industry is positive, with the Electronics - Semiconductors sector ranking in the top 35% of Zacks industries, suggesting potential for outperformance [8] Industry Context - Marvell Technology, another player in the semiconductor industry, is expected to report earnings of $0.61 per share, reflecting a year-over-year increase of 154.2%, with revenues projected at $1.88 billion, up 61.6% from the previous year [9][10]

Company Performance - Heron Therapeutics reported quarterly earnings of $0.01 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share, and improving from a loss of $0.02 per share a year ago, representing an earnings surprise of 200% [1] - The company posted revenues of $38.9 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.93%, compared to revenues of $34.67 million in the same quarter last year [2] - Over the last four quarters, Heron Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Heron Therapeutics shares have increased by approximately 39.2% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $37.68 million, and for the current fiscal year, it is $0.01 on revenues of $157.15 million [7] Industry Outlook - The Medical - Drugs industry, to which Heron Therapeutics belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]

Group 1 - Global Payments reported quarterly earnings of $2.82 per share, exceeding the Zacks Consensus Estimate of $2.69 per share, and up from $2.59 per share a year ago, representing an earnings surprise of 4.83% [1] - The company posted revenues of $2.2 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.25%, and compared to year-ago revenues of $2.18 billion [2] - Over the last four quarters, Global Payments has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed, losing about 29.3% since the beginning of the year, compared to the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the coming quarter is $3.05 on revenues of $2.35 billion, and for the current fiscal year, it is $12.20 on revenues of $9.29 billion [7] - The Financial Transaction Services industry, to which Global Payments belongs, is currently in the top 35% of Zacks industries, indicating a favorable outlook [8]

Company Performance - Madison Square Garden Entertainment (MSGE) reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, and showing a significant increase from earnings of $0.06 per share a year ago, representing an earnings surprise of 32% [1] - The company posted revenues of $242.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.94%, and an increase from year-ago revenues of $228.31 million [2] - Over the last four quarters, MSGE has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance and Outlook - MSGE shares have declined approximately 4.6% since the beginning of the year, compared to a decline of 3.9% for the S&P 500 [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.39 on revenues of $175.19 million, and $1.04 on revenues of $952.32 million for the current fiscal year [7] - The current Zacks Rank for MSGE is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Media Conglomerates industry, to which MSGE belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.71%. A quarter ago, it was expected that this company would post a loss of $1.10 per share when it actually produced a loss of $1.09, delivering a surprise of 0.91%.Over the last four quarters, the company has s ...